{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:01:47Z","timestamp":1789848107002,"version":"4.0.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objectives.<\/jats:bold>\n                    The aim of the study was to develop a diagnostic method for estrogen hypersensitivity syndrome in proliferative benign diseases of the female reproductive system. Using the example of endometriosis, changes in the activity of the chaperone protein Hsp90\u03b1 were determined as a diagnostic biomarker.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    The study included 60 women aged 30 to 50 years, thirty of whom had a laparoscopically confirmed diagnosis of endometriosis and 30 were included in the control group. After blood sampling to determine the baseline levels of Hsp90\u03b1, the patients were prescribed a single oral dose of estradiol valerate 2 mg tablet. The plasma Hsp90\u03b1 levels were remeasured 6 h later.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    No significant change (p&gt;0.05) in baseline Hsp90\u03b1 concentrations was found between the group of patients with endometriosis and the control group. Six hours after estradiol valerate administration, a significant difference (p&lt;0.001) in Hsp90\u03b1 levels was observed between the group of patients with endometriosis and the control group. The increase in Hsp90\u03b1 concentration following the test-load was also more pronounced in women with confirmed endometriosis compared to controls (27.29\u00b115.62 ng\/ml and 3.16\u00b14.36 ng\/ml, respectively) (p&lt;0.001). ROC analysis indicated that the absolute increase in Hsp90\u03b1 level of more than 8.6 ng\/ml in patients with endometriosis has a sensitivity of 0.93 and a specificity of 0.97 (compared to the control group). This change in relative concentration corresponded to an increase of over 28.7%.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    The increase in Hsp90\u03b1 plasma level of more than 30% within 6 h after the test-load is a specific criterion for estrogen hypersensitivity syndrome in endometriosis. Further investigation including other nosological forms (myoma, adenomyosis, endometrial hyperplasia) is required.\n                  <\/jats:p>","DOI":"10.2478\/enr-2026-0021","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:09:14Z","timestamp":1789844954000},"page":"207-212","source":"Crossref","is-referenced-by-count":0,"title":["Estrogens hypersensitivity syndrome in endometriosis"],"prefix":"10.2478","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-0468","authenticated-orcid":false,"given":"Nikolai Nikolaevich","family":"Rukhliada","sequence":"first","affiliation":[{"name":"1 Russian State Pediatric Medical University, Saint-Petersburg , Russia; Saint-Petersburg Research Institute of Emergency Medicine by I.I. Dzhanelidze , Saint-Petersburg , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Andreevna","family":"Dudova","sequence":"additional","affiliation":[{"name":"1 Russian State Pediatric Medical University, Saint-Petersburg , Russia; Saint-Petersburg Research Institute of Emergency Medicine by I.I. Dzhanelidze , Saint-Petersburg , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026091919090661537_j_enr-2026-0021_ref_001","doi-asserted-by":"crossref","unstructured":"Adamyan LV, Sonova MM, Loginova ON, Arslanyan KN. The role of aromatase in the development of genital endometriosis. Obstet Gynecol Reprod 10, 39\u201348, 2016.","DOI":"10.17749\/2313-7347.2016.10.4.039-048"},{"key":"2026091919090661537_j_enr-2026-0021_ref_002","doi-asserted-by":"crossref","unstructured":"Altukhova OB, Radzinskii VE, Polyakova IS, Churnosov MI. Involvement of estrogen and progesterone receptor gene polymorphism in the development of uterine fibroids. Obstet Gynecol 3, 127\u2013132, 2020.","DOI":"10.18565\/aig.2020.3.127-132"},{"key":"2026091919090661537_j_enr-2026-0021_ref_003","unstructured":"Artymuk NV, Gulyaeva LF, Zotova OA. Metabolism peculiaritirs and estrogenes reception in endometrial hyperplasia and endometriosis. Mat i ditya v Kuzbasse 1, 8\u201312, 2012."},{"key":"2026091919090661537_j_enr-2026-0021_ref_004","unstructured":"Babaeva NA, Ashrafyan LA, Antonova IB, Aleshikova OI, Ivashina SV. The role of hormonal imbalances in the carcinogenesis of tumors of the female reproductive system. Obstet Gynecol News Opin Training 1, 76\u201382, 2017."},{"key":"2026091919090661537_j_enr-2026-0021_ref_005","doi-asserted-by":"crossref","unstructured":"Babichev VN, Marova EI, Fedotcheva T, Shimanovskii NL. Estrogen receptors in the diagnosis and treatment of hormone-dependent tumors. Probl Endocrinol 55, 34\u201336, 2009.","DOI":"10.14341\/probl200955434-36"},{"key":"2026091919090661537_j_enr-2026-0021_ref_006","doi-asserted-by":"crossref","unstructured":"Backe SJ, Sager RA, Regan BR, Sit J, Major LA, Bratslavsky G, Woodford MR, Bourboulia D, Mollapour M. A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. Cell Rep 40, 111039, 2022.","DOI":"10.1016\/j.celrep.2022.111039"},{"key":"2026091919090661537_j_enr-2026-0021_ref_007","doi-asserted-by":"crossref","unstructured":"Bulun SE, Yildiz S, Adli M, Chakravarti D, Parker JB, Milad M, Yang L, Chaudhari A, Tsai S, Wei JJ, Yin P. Endometriosis and adenomyosis: shared pathophysiology. Ferti Steril 119, 746\u2013750, 2023.","DOI":"10.1016\/j.fertnstert.2023.03.006"},{"key":"2026091919090661537_j_enr-2026-0021_ref_008","doi-asserted-by":"crossref","unstructured":"Chantalat E, Valera MC, Vaysse C, Noirrit E, Rusidze M, Weyl A, Vergriete K, Buscail E, Lluel P, Fontaine E, Arnal JF, Lenfant F. Estrogen receptors and endometriosis. Int J Mol Sci 21, 2815, 2020.","DOI":"10.3390\/ijms21082815"},{"key":"2026091919090661537_j_enr-2026-0021_ref_009","doi-asserted-by":"crossref","unstructured":"Eldafira E, Prasasty VD, Abinawanto A, Syahfirdi L, Pujianto DA. Polymorphisms of estrogen receptor-\u03b1 and estrogen receptor-\u03b2 genes and its expression in endometriosis. Turk J Pharm Sci 18, 91\u201395, 2021.","DOI":"10.4274\/tjps.galenos.2019.94914"},{"key":"2026091919090661537_j_enr-2026-0021_ref_010","doi-asserted-by":"crossref","unstructured":"Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol 116, 135\u2013170, 2019. Guimaraes Ferreira LR, Cavalcanti T, Zomer M, Kondo W, Araujo Junior E, Kulak Junior J. Estrogen and progesterone receptors in endometriosis. Minerva Obstet Gynecol 74, 330\u2013336, 2022.","DOI":"10.23736\/S2724-606X.21.04888-0"},{"key":"2026091919090661537_j_enr-2026-0021_ref_011","doi-asserted-by":"crossref","unstructured":"Han SJ, Jung SY, Wu SP, Hawkins SM, Park MJ, Kyo S, Jun Qin, Lydon JP, Tsai SY, Tsai MJ, DeMayo FJ, O\u2019Malley BW. Estrogen receptor beta modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell 163, 960\u2013974, 2015.","DOI":"10.1016\/j.cell.2015.10.034"},{"key":"2026091919090661537_j_enr-2026-0021_ref_012","unstructured":"Itsekson A, Zolti M, Derzy I. Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same. Patent US20110262365A1, 2011-10-27."},{"key":"2026091919090661537_j_enr-2026-0021_ref_013","unstructured":"Lo Y, Tsuj D, Fu Y, U F, Sun S, Li M, Chan G, Lu C. Tumor biomarker. Patent RU2670768C2, 2018-10-25."},{"key":"2026091919090661537_j_enr-2026-0021_ref_014","doi-asserted-by":"crossref","unstructured":"MacLean JA II, Hayashi K. Progesterone actions and resistance in gynecological disorders. Cells 11, 647, 2022.","DOI":"10.3390\/cells11040647"},{"key":"2026091919090661537_j_enr-2026-0021_ref_015","doi-asserted-by":"crossref","unstructured":"Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis? Int J Mol Sci 20, 3822, 2019.","DOI":"10.3390\/ijms20153822"},{"key":"2026091919090661537_j_enr-2026-0021_ref_016","doi-asserted-by":"crossref","unstructured":"Martire FG, Costantini E, D\u2019Abate C, Schettini G, Sorrenti G, Centini G, Zupi E, Lazzeri L. Endometriosis and adenomyosis: from pathogenesis to follow-up. Curr Issues Mol Biol 47, 298, 2025.","DOI":"10.3390\/cimb47050298"},{"key":"2026091919090661537_j_enr-2026-0021_ref_017","doi-asserted-by":"crossref","unstructured":"Obermann WMJ. A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor \u03b1 methylation by the lysine methyltransferase SMYD2. J Biol Chem 293, 16479\u201316487, 2018.","DOI":"10.1074\/jbc.RA118.003578"},{"key":"2026091919090661537_j_enr-2026-0021_ref_018","doi-asserted-by":"crossref","unstructured":"Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G. Insabato L, Zullo F. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? Acta Obstet Gynecol Scand 98, 976\u2013987, 2019.","DOI":"10.1111\/aogs.13586"},{"key":"2026091919090661537_j_enr-2026-0021_ref_019","unstructured":"Rivero MdC, Salinas A, Saez Goni \u041cE, Moron Civantos FJ, Real LM, Galan JJ, Riuz Laza A, Royo JL. In vitro method for prognosis and\/or diagnosis of hypersensitivity to ooestrogens or to substances with ooestrogenic activity. Patent WO\/2008\/049953, 2008-05-02."},{"key":"2026091919090661537_j_enr-2026-0021_ref_020","unstructured":"Serov VN. Hormonal and metabolic changes in proliferative processes and precancer of female genital organs. Doctor Ru 2, 11\u201314, 2018."},{"key":"2026091919090661537_j_enr-2026-0021_ref_021","doi-asserted-by":"crossref","unstructured":"Simmen RC, Kelley AS. Reversal of fortune: estrogen receptor-\u03b2 in endometriosis. J Mol Endocrinol 57, F23\u2013F27, 2016.","DOI":"10.1530\/JME-16-0080"},{"key":"2026091919090661537_j_enr-2026-0021_ref_022","doi-asserted-by":"crossref","unstructured":"Sviridova NI, Tkachenko LV, Yakhontova MA, Gritsenko I, Maksimov SN, Puryaseva KA. Hyperplastic processes of the endometrium: modern approaches to diagnosis and treatment. Obstet Gynecol Reprod 18, 83\u201395, 2024.","DOI":"10.17749\/2313-7347\/ob.gyn.rep.2023.464"},{"key":"2026091919090661537_j_enr-2026-0021_ref_023","doi-asserted-by":"crossref","unstructured":"Wickramaratne A, Wickner S. Diptoindonesin G, a new Hsp90 drug. J Biol Chem 299, 102826, 2023.","DOI":"10.1016\/j.jbc.2022.102826"},{"key":"2026091919090661537_j_enr-2026-0021_ref_024","unstructured":"Xia H, Huang Z. High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody. Patent US20040142400A1, 2004-07-22."},{"key":"2026091919090661537_j_enr-2026-0021_ref_025","doi-asserted-by":"crossref","unstructured":"Yasar P, Ayaz G, User SD, Gupur G, Muyan M. Molecular mechanism of estrogen-estrogen receptor signaling. Re-prod Med Biol 16, 4\u201320, 2016.","DOI":"10.1002\/rmb2.12006"},{"key":"2026091919090661537_j_enr-2026-0021_ref_026","doi-asserted-by":"crossref","unstructured":"Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen receptor function: Impact on the human endometrium. Front Endocrinol 13, 827724, 2022.","DOI":"10.3389\/fendo.2022.827724"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2026-0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:09:22Z","timestamp":1789844962000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2026-0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,19]]},"published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.2478\/enr-2026-0021"],"URL":"https:\/\/doi.org\/10.2478\/enr-2026-0021","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}